MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in c...
Q1 2026
May 11, 2026
FY 2025
Mar 23, 2026
Q4 2025
Q3 2025
Nov 7, 2025
Q2 2025
Aug 11, 2025